Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9600+0.0300 (+1.55%)
At close: 04:00PM EDT
2.0100 +0.05 (+2.55%)
After hours: 04:20PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.9300
Open1.9200
Bid1.9000 x 900
Ask2.2600 x 800
Day's Range1.8900 - 1.9800
52 Week Range1.6000 - 7.0200
Volume520,305
Avg. Volume712,842
Market Cap106.778M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.1780
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 31, 2014
1y Target Est18.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PRTK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Paratek Pharmaceuticals, Inc.
    Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
Advertisement
Advertisement